Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perfect timing!! I get my ankle bracelet off Friday! I don't plan on bringing anything but will surely leave with something.
Deut
Hello all,
I have been a long time reader of the board and have nothing to add but my thanks.
I have NO formal education, worked in the steel casting area-very hard and hot-for 23 years. For the past 12 years I have worked for the automotive industry.
I was disappointed at adcom but only had approx. 3k shares then. I would like to Thank JL, HD, BB, Raf, and all the other knowledgeable posters that gave me the courage to add. I have around 12k at $2.5 approx. and some more that I bought at $12 and $15 the past couple weeks. So this is truly life changing for me because I'm not selling.
What I would like if anyone could help is information on Huntington's. I saw a post yesterday that this is where AMRN started.
I saw my uncle strapped to a bed in the 70's for the last 2 years of his life Logansport State Hospital due to this dreaded disease. I saw his boy die a terrible death from it. I also currently have a high school friend that has it whose mom died from it. His kids and sisters kids have not been tested but could have it.
Please forward any information on Huntington's whether AMRN or some other promising company to rodjy123@aol.com.
Again thanks to everyone for giving me the information to keep courage to stay in AMRN.
God bless,
Deut
NEOP
Mentioned them a couple years ago and they are going back on Amex today. Still have alot of catalysts to go.
http://advancedduediligence.blogspot.com/
Near-term catalysts 1Q-2Q11
-Top line data from Lymphoseek NEO3-09 Phase III study in Feb.
-Presentation of detailed NEO3-09 Phase III dataset.
-Submission of Lymphoseek NDA
-FDA pre-IND Meeting for RIGScan CR49
-New IND for RIGScan to reinitiate clinical development
-Clarification of full RIGS development & registration plan with FDA and EMA
-Possible listing on major exchange
Deut8:18
if the data was good off the bat, you announce the data and that the trial was successful, then meet with the fda. Since they must have had protocol violators that made the results miss the endpoint, before announcing the data, they met with the fda so they could put out press releases that the nda will eventually be filed because they will have several meetings with the fda.
at each meeting the fda will say do not file the data, it is crap but you will keep playing with the data and having more meetings, extending the defeat until you can sell your stock.
I have never seen a press release like this where the company met with the fda before announcing their data. why didn't they announce the data as soon as they had it, if it met the endpoints--drbio45
I believe that you haven't kept up with Neoprobe's story since they are a small co. and very much off the radar. The original trial was to do the Breast and Melanoma trial as phase llla then a Head and Neck squamous cell trial as phaselllb. They met the endpoints on the B&M and at the conferences Bupp has presented at recently has stated the the Head and Neck trials have, "NO misses to date" and "No negative surprises." Any other info can be found at:
http://advancedduediligence.blogspot.com/
I believe the meetings are to get approval for Breast and Melanoma designation prior to completing the H&N trial and then after completing the H&N they will proceed with filing for Sentential designation.
The cc should shed more light but I believe it is all good.
Deut 8:18
Deut 8:18
I have heard David Bupp, Neoprobe CEO, make that projection many times. That number is also confirmed in a Dutton report, and I know you don't like paid for reports but they get their info from somewhere and yes Dutton is out-of-business but I still believe the report to be factual, that can be found on the Neoprobe Advanced Blog: http://advancedduediligence.blogspot.com/
Rigs projection from the blog:
For prognostic applications, third party consultants have estimated that the RIGS drug could command $6,000 per operative dose. With 149,000 cases of colon cancer in the U.S. (American Cancer Society) and 940,000 cases worldwide (World Health Organization) the potential annual sales for RIGS ranges from $1 Billion to $6 Billion per year, depending on market penetration. Consultants have pegged the latest estimates at $2.4 Billion.
You can listen to the webcast Thurs and see what he says: http://finance.yahoo.com/news/Neoprobe-to-Present-at-Rodman-bw-3840182883.html?x=0&.v=2
Good luck,
Deut 8:18
Neop: This is why it is a good deal. Rigs is moving forward and is a 2B+ drug.
http://finance.yahoo.com/news/Laureate-Pharma-and-Neoprobe-bw-1301075644.html?x=0&.v=1
Deut 8:18
Neop:
Todays close $1.32.
The $3.45M was to get Rigs moving.
I believe they have alot going on. Rigs, 2B+, should have been approved in 1995 as it save lives and Lymphoseek, 250M, in final phase lll has had stellar results.
If you want more info you can research the link to the blog.
http://advancedduediligence.blogspot.com/
Good luck,
Deut 8:18
Neoprobe news:
http://finance.yahoo.com/news/Neoprobe-to-Receive-35-bw-611188562.html?x=0&.v=1
Chart looks good:
http://finance.yahoo.com/q/bc?s=NEOP.OB&t=6m&l=on&z=m&q=l&c=
Rigs is 1.6B drug in rest of world and over 2B with USA.
Blog:
http://advancedduediligence.blogspot.com/
Deut 8:18
NEOP. Good post by DDbuyer on IV about todays CC:
http://www.investorvillage.com/groups.asp?mb=16085&mn=1174&pt=msg&mid=7342740
Cardinal Health has exclusive distributorship.
From link:http://finance.yahoo.com/news/Neoprobe-Announces-Positive-bw-15170343.html?.v=1
Lymphoseek identified 40 nodes that did not contain the vital blue dye. Of those 40 nodes, 19% were determined by pathology to contain tumor. None of the nodes that contained only vital blue dye were found to contain tumor. Two of Dr. Sondak’s patients experienced a serious adverse event (SAE), but neither of the SAEs was considered to be related to Lymphoseek.
Lymphoseek clears faster saving time also.
IV board: http://www.investorvillage.com/groups.asp?mb=16085
Blog:http://neopstock.blogspot.com/
Deut 8:18
Neop earnings and CC info:
http://biz.yahoo.com/bw/090310/20090310006304.html?.v=1
Deut8:18
Neop is steadily going up and sooner or later there should be some news on the Lymphoseek and Rigs. Here is a link to a new blog for Neop:
http://neoprobe.blogspot.com/
Yes, but they have downgraded it before. Here is the link to all Duttons reports with their recommendations:
http://www.jmdutton.com/research/NEOP/index.html
and here is their fee that is listed at the bottom of the page.
The Firm does not accept any equity compensation. Anyone may enroll a company for research coverage, which currently costs US $35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $134,000 from the Company for 18 Research Reports with coverage commencing on 07/26/2004. Reports are performed on behalf of the public, and are not a service to any company. The analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests and insure independence. Please read full disclosure and other reports and notes on the Company at www.DuttonAssociates.com.
The views expressed in this research report or note accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by Dutton Associates is in any way related to the specific recommendations or views contained in this research report or note.
WBB also has a $3.50 target and they do not get compsensated.
Dutton and Assoc. raises Neoprobe price target to $3.90
http://www.jmdutton.com/research/neop/reports/neop_report_121808.pdf
deut8:18
Bladerunner,
Here is some information that misspinkard may like if you would want to post it on that cancer patient website to her. First I am long Neoprobe so yes I am a pumper but the Rigs technology works and I believe in it. Here is the survival data that was performed on stage 4 patients.
An independent clinical research organization performed a survival analysis based on the patients enrolled in NEO2-14, the pivotal clinical study that served as the primary evidence submitted to the FDA in 1997 as the basis for the Company's Biologic License Application (BLA). Ninety-four of 109 evaluable patients determined by the FDA were available for analysis. The study found the five-year mortality rates for the following:
91% mortality for those patients diagnosed with positive spread of disease without the aid of RIGS (Traditional+)
53% mortality for those patients diagnosed with positive spread of disease with the aid of RIGS positive but were otherwise traditionally negative( RIGS+/traditional-)
25% mortality for those patients who have no evidence of spread of disease with the aid of RIGS (RIGS-/Traditional-)
Source: Schneebaum et. al., Budapest 2004
Neoprobe could get a CMA, allows patients to get the surgery while the trials are going on, in Europe as early as Q4 of 2009/Q1-2010 so she may want to keep her eye on this technology if she still has colon cancer. Here is a blog that has more info on Neoprobe and Rigs.
http://www.investorvillage.com/blog.asp?b=3A649286B78CB5E9
Deut 8:18
Dew Dilligence,
I would like to know what you think about NEOP. The only other time I read this board was when I had DNDN and I wish I would have listened to you. I own alot of NEOP and would like an opinion that not is from Investor's Village.
Has any compnay recieved the conditional marketing authorization (CMA)that just begun this year in Europe?
Thank you,
Deut 8:18
Please delete the multiple email. Thanks eom
Thanks for checking into that for me Wolfgang.
Deut 8:18
Wolfgang, I don't know any German but does this link provide anywhere that shows VCH's holdings?
http://www.netfonds24.de/VCH-Expert-Biotech.html
Thanks,
Deut 8:18
test eom